Celgene Corporation (CELG) : E&g Advisors Lp scooped up 750 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 11, 2016. The investment management firm now holds a total of 14,318 shares of Celgene Corporation which is valued at $1,492,938.Celgene Corporation makes up approximately 0.88% of E&g Advisors Lp’s portfolio.
Other Hedge Funds, Including , Dynamic Advisors Solutions reduced its stake in CELG by selling 765 shares or 28.46% in the most recent quarter. The Hedge Fund company now holds 1,923 shares of CELG which is valued at $200,511. Celgene Corporation makes up approx 0.08% of Dynamic Advisors Solutions’s portfolio.Advisory Services Network boosted its stake in CELG in the latest quarter, The investment management firm added 889 additional shares and now holds a total of 36,582 shares of Celgene Corporation which is valued at $3,807,089. Celgene Corporation makes up approx 0.72% of Advisory Services Network’s portfolio.Eqis Capital Management reduced its stake in CELG by selling 280 shares or 0.86% in the most recent quarter. The Hedge Fund company now holds 32,211 shares of CELG which is valued at $3,391,496. Celgene Corporation makes up approx 0.21% of Eqis Capital Management’s portfolio.Harbour Capital Advisors reduced its stake in CELG by selling 80 shares or 0.74% in the most recent quarter. The Hedge Fund company now holds 10,799 shares of CELG which is valued at $1,137,027. Celgene Corporation makes up approx 0.61% of Harbour Capital Advisors’s portfolio.
Celgene Corporation closed down -2.63 points or -2.52% at $101.64 with 34,28,438 shares getting traded on Tuesday. Post opening the session at $103.6, the shares hit an intraday low of $101.021 and an intraday high of $103.881 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.